High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 1877-1881

  Jin, Han Young ^a   Yang, Tae Hyun ^a   Kim, Doo Il ^a   Chung, Sang Ryul ^a   Seo, Jeong Sook ^a   Jang, Jae Sik ^a   Kim, Dae Kyeong ^a   Kim, Dong Kie ^a   Kim, Ki Hun ^a   Seol, Sang Hoon ^a   Nam, Chang Wook ^b   Hur, Seung Ho ^b   Kim, Woong ^c   Park, Jong Seon ^c   Kim, Young Jo ^c   Kim, Dong Soo ^a  

^a Inje University College of Medicine   (South Korea)

^b Dongsan Medical Center   (South Korea)

^c Yeungnam University Hospital   (South Korea)

Author keywords

Myocardial infarction; Platelet reactivity; Point of care assay

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CORONARY STENT; DOSE RESPONSE; DRUG EFFECT; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; POINT OF CARE TESTING; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; TREATMENT OUTCOME;

MYOCARDIAL INFARCTION; PLATELET REACTIVITY; POINT-OF-CARE ASSAY;

AGED; ASPIRIN; BLOOD PLATELETS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84883306859     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.04.154     Document Type: Article

References (28)

1. M. Gawaz Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium Cardiovasc Res 61 2004 498 511
2. G. Campo, M. Valgimigli, and D. Gemmati Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study J Am Coll Cardiol 48 2006 2178 2185
3. C.W. Hamm, J.P. Bassand, and S. Aqewall ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
4. W. Hochholzer, D. Trenk, and M. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
5. J. Mega, S. Close, and S. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
6. P.G. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 24 2007 2312 2317
7. T. Cuisset, C. Frere, and J. Quilici Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients Am J Cardiol 104 2009 1078 1082
8. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
9. G. Parodi, R. Marcucci, and R. VAlenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndrome undergoing PCI JAMA 306 2011 1215 1223
10. M.A. Castro, C.C. Ramon, and D.A. Nieto Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome Rev Esp Cardiol 62 2009 126 135
11. R. Marcucci, A. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
12. M.J. Price, S. Endemann, and R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
13. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
14. A.R. Hobson, G. Petley, G. Morton, K.D. Dawkins, and N.P. Curzen Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with drug-eluting stent thrombosis whilst on dual antiplatelet therapy Thromb J 29 6 2008 1 6
15. D. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
16. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS randomized trial JAMA 305 2011 1097 1105
17. M.J. Price, D.J. Angiolillo, and P.S. Teirstein Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial Circulation 124 2011 1132 1137
18. Z. Huczek, K. Filipiak, and J. Kochman Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty - influence on myocardial reperfusion, left ventricular performance, and clinical events Am Heart J 154 2007 62 70
19. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
20. T. Geisler, M. Kapp, and K. Ghring-Frischholz Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart 94 2008 743 747
21. I. Fuchs, M. Frossard, A. Spiel, E. Riedmller, A.N. Laggner, and B. Jilma Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS J Thromb Haemost 4 2006 2547 2552
22. F. Cesari, R. Marcucci, and R. Caporale Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy Thromb Haemost 99 2008 930 935
23. Z. Desta, X. Zhao, J.-G. Shin, and D. Flockhart Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958
24. Writing Committee Members G.N. Levine, and E.R. Bates ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Circulation 124 2011 e574 e651
25. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndrome N Engl J Med 357 2007 2001 2015
26. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndrome N Engl J Med 361 2009 1045 1057
27. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
28. X.D. Wang, D.F. Zhang, S.W. Zhuang, and Y. Lai Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance Clin Cardiol 34 5 2011 332 338